Posted by Michael Wonder on 04 Jan 2018
Landmark schizophrenia data that bring hope in breaking the cycle of hospitalisation and incarceration receive FDA approval for inclusion in Invega Sustenna (paliperidone palmitate) label
3 January 2017 - Invega Sustenna is the first and only antipsychotic to demonstrate superior effectiveness in delaying time to relapse versus a group of seven commonly prescribed oral antipsychotics in adults with schizophrenia who face common real-world circumstances.
Janssen today announced Invega Sustenna (paliperidone palmitate), a once-monthly schizophrenia treatment, is the first and only antipsychotic to have the U.S. FDA approve the inclusion of real-world data in its product labelling. These data come from the Paliperidone Palmitate Research In Demonstrating Effectiveness (PRIDE) study and demonstrate:
The superior effectiveness of Invega Sustenna versus a group of seven commonly prescribed oral antipsychotics in delaying time to relapse, and
The time to first psychiatric hospitalisation or arrest and/or incarceration was significantly longer for people treated with Invega Sustenna versus these same commonly prescribed oral antipsychotics.
